TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26943500
Drug: Supplementary oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplementary oral immunonutrition (IN) (Oral Impact®, Nestlé) to reach a goal of 1.5 g protein/kg BW, administered for seven days before surgery.
Study: 26943500
Drug: Supplementary oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplementary oral immunonutrition (IN) (Oral Impact®, Nestlé)
Study: 11206234
Drug: Azelastine nasal
Normalized name: azelastine nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelastine nasal spray (two sprays per nostril twice daily, 1.1 mg/day)
Study: 2645030
Drug: 5 per
Normalized name: 25 Person ANSI KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 per cent acyclovir ointment
Study: 23819410
Drug: Combined physiotherapeutic
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined physiotherapeutic treatment including collar zone massage, orthotraction therapy, and soft cervical collar
Study: 8345288
Drug: Loteprednol etabonate
Normalized name: Loteprednol Etabonate
DrugBank: Loteprednol etabonate (DB14596)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Loteprednol etabonate (LE) 0.5% suspension, 1 drop 4 times daily for 42 days
Study: 8345288
Drug: Prednisolone acetate
Normalized name: Prednisolone Acetate
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone acetate (PA) 1.0%, 1 drop 4 times daily for 42 days
Study: 3731678
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg PPA (sustained-release preparation)
Study: 29861230
Drug: Instrument-assisted soft
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instrument-assisted soft tissue mobilization (IASTM) treatments (six treatments over three weeks)
Study: 25284194
Drug: 100 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 μg of sodium selenite once daily for 365 consecutive days
Study: 20814325
Drug: Osmotic-release oral
Normalized name: nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Osmotic-release oral system methylphenidate (OROS MPH)
Study: 20814325
Drug: Methylphenidate transdermal
Normalized name: methylphenidate Transdermal System
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate transdermal system (MTS) with dose escalation to 30 mg per 9 hours
Study: 20814325
Drug: Osmotic-release oral
Normalized name: nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Osmotic-release oral system methylphenidate (OROS MPH) with dose escalation to 54 mg
Study: 20814325
Drug: Methylphenidate transdermal
Normalized name: methylphenidate Transdermal System
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate transdermal system (MTS) and OROS MPH
Study: 17650795
Drug: Fuzheng Jiedu
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fuzheng Jiedu Granule (FJG) plus Western medicine
Study: 14634543
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg transdermal estradiol
Study: 14634543
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg transdermal estradiol
Study: 8530994
Drug: Real low-level
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real low-level laser (LLL) treatment (4 x 6 J per treatment, total of 20 treatments)
Study: 8530994
Drug: Placebo low-level
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo low-level laser treatment
Study: 8530994
Drug: Real low-level
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real low-level laser (LLL) treatment
Study: 1824798
Drug: High-dose medroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose medroxyprogesterone acetate (HD MAP) 1,000 mg b.i.d. p.o.
Study: 1824798
Drug: High-dose medroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose medroxyprogesterone acetate (HD MAP)
Study: 1824798
Drug: High-dose medroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose medroxyprogesterone acetate (HD MAP) and Oophorectomy (OPX)
Study: 4087291
Drug: Riboflavin 5
Normalized name: riboflavin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riboflavin 5 mg dose
Study: 4087291
Drug: Larger doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Larger doses of riboflavin
Study: 24753478
Drug: Nonivamide treatment
Normalized name: Nonivamide
DrugBank: Nonivamide (DB11324)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonivamide treatment (NT) - 0.15 mg nonivamide added to 75 g glucose in 300 mL water
Study: 24753478
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (CT) - 75 g glucose in 300 mL water
Study: 24753478
Drug: Nonivamide treatment
Normalized name: Nonivamide
DrugBank: Nonivamide (DB11324)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonivamide treatment (NT)
Study: 23536015
Drug: Breast cancer
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breast cancer survivors treated with chemotherapy
Study: 19887889
Drug: Supportive-experiential group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive-experiential group therapy
Study: 11447732
Drug: GnRH-agonist leuprorelin
Normalized name: leuprorelin
DrugBank: Leuprolide (DB00007)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH-agonist leuprorelin acetate depot (LAD) 3.75 mg subcutaneously per month
Study: 11447732
Drug: Gestagen lynestrenol
Normalized name: lynestrenol
DrugBank: Lynestrenol (DB12474)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gestagen lynestrenol (LYN) 5 mg orally twice per day
Study: 8033761
Drug: Naltrexone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (100 mg on Days 1 and 3, and 150 mg on Day 5)
Study: 1111465
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (intermittent melphalan and prednisone)
Study: 25046944
Drug: Pinaverium Bromide
Normalized name: pinaverium bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pinaverium Bromide Tablet
Study: 15661459
Drug: Nefopam 80
Normalized name: nefopam
DrugBank: Nefopam (DB12293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefopam 80 mg continuous infusion
Study: 15661459
Drug: Nefopam 120
Normalized name: nefopam
DrugBank: Nefopam (DB12293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefopam 120 mg continuous infusion
Study: 15661459
Drug: Placebo continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo continuous infusion
Study: 12878920
Drug: Naltrexone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (50 mg daily) + Cognitive Behavioral Therapy (CBT)
Study: 12878920
Drug: Naltrexone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (50 mg daily) + Supportive Therapy
Study: 12878920
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + Supportive Therapy
Study: 9988404
Drug: Cabergoline (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabergoline (0.5 mg orally every week)
Study: 7487796
Drug: 75-200 mg
Normalized name: carbidopa
DrugBank: Carbidopa (DB00190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75-200 mg dosage range of tricyclic antidepressant
Study: 7487796
Drug: 75-425 mg
Normalized name: urea 425 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75-425 mg dosage range of tricyclic antidepressant
Study: 31714584
Drug: ATRA plus
Normalized name: ATRA
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ATRA plus chemotherapy (CT)
Study: 29344773
Drug: Hybrid intervention
Normalized name: Amaranthus hybridus pollen
DrugBank: Amaranthus hybridus pollen (DB15503)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybrid intervention (combination of online sexual health program and supplemental class lessons)
Study: 24131664
Drug: Epidural oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural oxycodone (0.1 mg kg(‐1))
Study: 24131664
Drug: Intravenous oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous oxycodone (0.1 mg kg(‐1))
Study: 22735432
Drug: Hormone levels
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone levels and metabolic syndrome components
Study: 16089141
Drug: Shenqi fuzheng
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenqi fuzheng injection (SFI)
Study: 16089141
Drug: No Shenqi
Approvals — FDA: no, EMA: no, PMDA: no
Description: No Shenqi fuzheng injection (SFI)
Study: 22568921
Drug: Linezolid 600
Normalized name: linezolid 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linezolid 600 mg IV or orally every 12 h
Study: 22568921
Drug: Vancomycin 15
Normalized name: vancomycin 1500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin 15 mg/kg or 1 g IV every 12 h
Study: 19293413
Drug: Pactimibe 100
Normalized name: Pactimibe
DrugBank: Pactimibe (DB12971)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pactimibe 100 mg/d
Study: 12507242
Drug: 3i threaded
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3i threaded implants (self-tapping, ICE, Osseotite)
Study: 8445432
Drug: Intrathecal methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intrathecal methotrexate (10 mg) twice weekly
Study: 8445432
Drug: Thiotepa (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiotepa (10 mg) twice weekly
Study: 30346225
Drug: Energy-dense enteral
Normalized name: Senergy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Energy-dense enteral nutrition (1.5 kcal/ml)
Study: 27060053
Drug: Phosphodiesterase type
Normalized name: collagen type I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphodiesterase type 5 inhibitor
Study: 16701078
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) for 3 months
Study: 21927686
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil infusion at the rate of 0.17 µg/kg/min
Study: 7793548
Drug: Epidural infusion
Normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural infusion of bupivacaine 0.125% with diamorphine 0.0025%
Study: 7793548
Drug: Epidural infusion
Normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural infusion of bupivacaine 0.062% with diamorphine 0.0025%
Study: 7793548
Drug: Epidural infusion
Normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural infusion of bupivacaine 0.031% with diamorphine 0.0025%
Study: 7793548
Drug: All bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: All bupivacaine infusions
Study: 2569488
Drug: Metronidazole (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (0.6 g/day)
Study: 2569488
Drug: Sulfasalazine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfasalazine (2 g/day)
Study: 19550340
Drug: Dexmedetomidine (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (loading dose 1 microg/kg for 10 min followed by infusion of 0.2-0.7 microg/kg/h)
Study: 19550340
Drug: Midazolam (bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (bolus dose 0.04 mg/kg followed by infusion of 0.04-0.08 mg/kg/h)
Study: 9692106
Drug: Capsaicin inhalation
Normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsaicin inhalation after combined beta- and atropinic blockade in mild asthmatics
Study: 9692106
Drug: Capsaicin inhalation
Normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsaicin inhalation in nocturnal asthmatics after atropinic blockade alone
Study: 9692106
Drug: Capsaicin inhalation
Normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsaicin inhalation in normal subjects after atropine plus propranolol
Study: 3653590
Drug: Diltiazem 60
Normalized name: DILTIAZEM 60MG 12HR CAP,SA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 60 mg tid
Study: 30138085
Drug: HDMTX (Berlin-Frankfurt-Muenster
Approvals — FDA: no, EMA: no, PMDA: no
Description: HDMTX (Berlin-Frankfurt-Muenster high-dose intravenous MTX regimen)
Study: 24024826
Drug: Stepped care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stepped care intervention including self-help material, chat forum, FAQ section, and cognitive behavioral therapy (CBT) administered by a personal therapist if symptoms persist.
Study: 19159941
Drug: Post-tonsillectomy injection
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-tonsillectomy injection of bupivacaine
Study: 10669363
Drug: Trivalent live
Normalized name: influenza vaccine trivalent live 2024-2025 (2 yrs-49 yrs) 10exp6.5-7.5 FF unit/0.2 mL NASAL NASAL SPRAY SYRINGE (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent live attenuated influenza vaccine (LAIV)
Study: 9107443
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy 0.5/120 mg
Study: 9107443
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy 0.5/180 mg
Study: 9107443
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy 2/180 mg
Study: 9107443
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy 2/240 mg
Study: 9107443
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy 8/240 mg
Study: 1315560
Drug: Renin inhibitor
Normalized name: Renin inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renin inhibitor CGP 38560A (125 micrograms kg‐1)
Study: 1315560
Drug: Renin inhibitor
Normalized name: Renin inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renin inhibitor CGP 38560A (250 micrograms kg‐1)
Study: 1315560
Drug: ACE inhibitor
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitor lisinopril (20 mg)
Study: 30957391
Drug: Clopidogrel-aspirin dual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel-aspirin dual treatment
Study: 29871668
Drug: Frequent, rapid,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frequent, rapid, on-site testing and treatment (TnT)
Study: 26740254
Drug: High-dose black
Normalized name: acid black 52
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose black raspberry (2500 mg/d)
Study: 26740254
Drug: Moderate-dose black
Normalized name: acid black 52
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-dose black raspberry (1500 mg/d)
Study: 24699059
Drug: Intravenous tissue‐type
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tissue‐type plasminogen activator followed by endovascular treatment
Study: 24699059
Drug: Intravenous tissue‐type
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tissue‐type plasminogen activator alone
Study: 17185020
Drug: Idursulfase at
Normalized name: Idursulfase
DrugBank: Idursulfase (DB01271)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Idursulfase at 0.15 mg/kg infused every other week
Study: 17185020
Drug: Idursulfase at
Normalized name: Idursulfase
DrugBank: Idursulfase (DB01271)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Idursulfase at 0.5 mg/kg
Study: 17185020
Drug: Idursulfase at
Normalized name: Idursulfase
DrugBank: Idursulfase (DB01271)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Idursulfase at 1.5 mg/kg
Study: 17185020
Drug: Idursulfase (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idursulfase (all doses)
Study: 8122594
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of dipyridamole intravenously over 1 hour, starting immediately before the procedure (group 1)
Study: 8122594
Drug: Dipyridamole administered
Normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dipyridamole administered before the procedure (group 2)
Study: 8122594
Drug: No dipyridamole
Normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No dipyridamole administered (group 3)
Study: 983794
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g niceritrol given three times daily (1 g X 3)
Study: 983794
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g niceritrol given twice daily (1.5 g X 2)
Study: 12668405
Drug: Cognitive-behavioural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural therapy (CBT) plus treatment as usual (TAU)
Study: 17156174
Drug: Dihydrocodeine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydrocodeine (30 mg or 60 mg tablets)
Study: 17156174
Drug: Methadone mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone mixture (1 mg/ml)
Study: 10699069
Drug: Postoperative adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative adjuvant chemotherapy alone (n = 348)
Study: 10699069
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with postoperative radiotherapy (n = 346)
Study: 10699069
Drug: 5-FU plus
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU plus LV chemotherapy in male patients (n = 200)
Study: 10699069
Drug: MOF chemotherapy
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MOF chemotherapy in male patients (n = 207)
Study: 30053896
Drug: PF-06438179/GP1111 (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06438179/GP1111 (3 mg/kg intravenous at weeks 0, 2, and 6, then every 8 weeks; dose escalation to 5 mg/kg allowed starting at week 14)
Study: 30053896
Drug: Infliximab-EU (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infliximab-EU (3 mg/kg intravenous at weeks 0, 2, and 6, then every 8 weeks; dose escalation to 5 mg/kg allowed starting at week 14)
Study: 30053896
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (PF-06438179/GP1111 and infliximab-EU)
Study: 26843085
Drug: Multivitamin supplement
Normalized name: Vi-Daily Multivitamin Supplement Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivitamin supplement (Multicentrum, Pfizer, 1 tablet/day) during 3 months
Study: 26843085
Drug: Multivitamin supplement
Normalized name: Vi-Daily Multivitamin Supplement Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivitamin supplement (Multicentrum, Pfizer, 1 tablet/day) during 12 months
Study: 20224262
Drug: 3 instillations
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 instillations of 1% silver nitrate solution
Study: 20224262
Drug: 9 instillations
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 instillations of 1% silver nitrate solution
Study: 17391132
Drug: Enteric-coated mycophenolate
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enteric-coated mycophenolate sodium (EC-MPS) 720 mg b.i.d.
Study: 17391132
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) 1000 mg b.i.d.
Study: 10683057
Drug: 100 mg/d
Normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/d of androstenedione
Study: 10683057
Drug: 300 mg/d
Normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg/d of androstenedione
Study: 10683057
Drug: 0 mg/d
Normalized name: Arixtra 10 mg/dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg/d of androstenedione (control)
Study: 8364949
Drug: Ketorolac (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac (30 mg intramuscularly every 3 to 6 hours as needed, followed by 10 mg every 4 to 6 hours)
Study: 8364949
Drug: Meperidine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine (100 mg intramuscularly every 3 to 6 hours as needed, followed by acetaminophen/codeine (600 mg/60 mg) orally every 4 to 6 hours)
Study: 20584668
Drug: Parecoxib sodium
Normalized name: parecoxib sodium
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Parecoxib sodium 40 mg intravenously, repeated at 24 and 48 hours post-operation
Study: 10391601
Drug: Intrathecal bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal bupivacaine (17.5 mg)
Study: 10391601
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine (0.6 mg) and intrathecal bupivacaine (17.5 mg)
Study: 6658432
Drug: Pyrazinamide (PZA)
Normalized name: Pyrazinamide
DrugBank: Pyrazinamide (DB00339)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pyrazinamide (PZA) at 25 mg/kg body weight
Study: 6658432
Drug: Ethambutol (EMB)
DrugBank: Ethambutol (DB00330)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethambutol (EMB) at 25 mg/kg body weight
Study: 29944706
Drug: Daily self-weighing
Normalized name: DAILY SELF DISCOVERY SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily self-weighing (DSW) and daily activity tracking (DAT)
Study: 29944706
Drug: Daily activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily activity tracking (DAT)
Study: 24946564
Drug: Orthopedics lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orthopedics lotion fumigation treatment (treatment group)
Study: 24946564
Drug: Sodium hyaluronate
Normalized name: sodium hyaluronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium hyaluronate intra-articular injection (control group)
Study: 24946564
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (treatment and control)
Study: 23575046
Drug: Preemptive fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Preemptive fentanyl 25 μg (0.5 ml) prior to fentanyl 125 μg (2.5 ml)
Study: 23575046
Drug: Preemptive fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Preemptive fentanyl 25 μg (0.5 ml) prior to fentanyl 150 μg (3 ml)